Technology area: Biotechnology & Pharmaceuticals
3 pending office actions • 3 art units • 3 examiners • 0 of 3 (0%) have an AI response strategy ready • 2 patents granted in the last 365 days
Minovia Therapeutics Ltd. has 3 pending office actions in Biotechnology & Pharmaceuticals. Each matter is assigned to a separate examiner and a separate art unit, indicating fully distributed examination within the reported portfolio.
KNIGHT, TERESA E is the busiest examiner, with 1 pending matter. Counsel should avoid assuming that arguments developed for one matter will receive identical treatment in the other assignments.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting + other | 1 (33%) |
| Multi-statute (no §101) | 2 (67%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| KNIGHT, TERESA E | 1 | 66.1% | +48.1% |
| AMICK, THOMAS RUSSE | 1 | 73.8% | +29.4% |
| KIM, TAEYOON | 1 | 51.4% | +52.2% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18714544 | MITOCHONDRIAL AUGMENTATION THERAPY FOR MYELODYSPLASTIC SYNDROME | AMICK, THOMAS RUSSE | — |
| 17912022 | MITOCHONDRIAL AUGMENTATION THERAPY | KIM, TAEYOON | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18817206 | MITOCHONDRIAL AUGMENTATION THERAPY WITH STEM CELLS ENRICHED WITH FUNCTIONAL MITOCHONDRIA | KNIGHT, TERESA E | — |
| 18714544 | MITOCHONDRIAL AUGMENTATION THERAPY FOR MYELODYSPLASTIC SYNDROME | AMICK, THOMAS RUSSE | — |
| 17912022 | MITOCHONDRIAL AUGMENTATION THERAPY | KIM, TAEYOON | — |
| Art Unit | Apps |
|---|---|
| 1634 | 1 |
| 1638 | 1 |
| 1631 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18817206 | MITOCHONDRIAL AUGMENTATION THERAPY WITH STEM CELLS ENRICHED WITH FUNCTIONAL MITOCHONDRIA | KNIGHT, TERESA E | 1634 | §103§112DP | Non-Final OA | — | Pending | Aug 27, 2024 |
| 18714544 | MITOCHONDRIAL AUGMENTATION THERAPY FOR MYELODYSPLASTIC SYNDROME | AMICK, THOMAS RUSSE | 1638 | §102§112 | Non-Final OA | — | Pending | May 29, 2024 |
| 17912022 | MITOCHONDRIAL AUGMENTATION THERAPY | KIM, TAEYOON | 1631 | §102§103§112Other | Non-Final OA | — | Pending | Sep 15, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialMinovia Therapeutics Ltd. has 3 pending office actions as of October 2026, spread across 3 art units and 3 examiners.
Teresa E Knight has the most, with 1 of Minovia Therapeutics Ltd.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
